Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Science Translational Medicine|July 11, 2014
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.
European Urology|October 23, 2022
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex BiasMing-Jun Shi, Jacqueline Fontugne, Aura Moreno-Vega, et al.
Journal of Oncology Practice|July 12, 2017
Renal Medullary Carcinoma: Establishing Standards in PracticeKathryn E Beckermann, Deva Sharma, Shruti Chaturvedi, et al.
Cancer Discovery|March 6, 2012
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targetsHimisha Beltran, David S Rickman, Kyung Park, et al.
Journal of Clinical Pathology|September 29, 2021
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortFriederike Kullmann, Pamela L Strissel, Reiner Strick, et al.
Nature Communications|January 18, 2019
Recurrent activating mutations of PPARγ associated with luminal bladder tumorsNatacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot, et al.
Environment International|December 22, 2019
Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypesStella Koutros, Manolis Kogevinas, Melissa C Friesen, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Science Translational Medicine|July 11, 2014
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotypeSandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, et al.
European Urology|October 23, 2022
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex BiasMing-Jun Shi, Jacqueline Fontugne, Aura Moreno-Vega, et al.
Journal of Oncology Practice|July 12, 2017
Renal Medullary Carcinoma: Establishing Standards in PracticeKathryn E Beckermann, Deva Sharma, Shruti Chaturvedi, et al.
Cancer Discovery|March 6, 2012
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targetsHimisha Beltran, David S Rickman, Kyung Park, et al.
Journal of Clinical Pathology|September 29, 2021
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortFriederike Kullmann, Pamela L Strissel, Reiner Strick, et al.
Nature Communications|January 18, 2019
Recurrent activating mutations of PPARγ associated with luminal bladder tumorsNatacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot, et al.
Environment International|December 22, 2019
Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypesStella Koutros, Manolis Kogevinas, Melissa C Friesen, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
The Journal of Clinical Investigation|May 3, 2022
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancerMathieu Rouanne, Julien Adam, Camélia Radulescu, et al.
Pageof 21